

# Myron J Levin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5969214/publications.pdf>

Version: 2024-02-01

76  
papers

4,977  
citations

186265

28  
h-index

91884

69  
g-index

77  
all docs

77  
docs citations

77  
times ranked

4677  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 226, 1943-1948.	4.0	3
2	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2022, 97, 90-98.	4.1	13
3	A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019â€“2020 Influenza Season in the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab604.	0.9	11
4	Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System. <i>Journal of Infectious Diseases</i> , 2022, 226, 757-765.	4.0	2
5	Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 485-490.	3.6	7
6	Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 744-752.	2.6	30
7	Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled <i>post hoc</i> analysis on two parallel randomized trials. <i>Rheumatology</i> , 2021, 60, 1226-1233.	1.9	26
8	Vaccines for older adults. <i>BMJ, The</i> , 2021, 372, n188.	6.0	36
9	Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. <i>Journal of Virology</i> , 2021, 95, .	3.4	18
10	Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged â‰¥ 65 Years in the US during the 2019â€“20 Influenza Seasonâ€”A Retrospective Cohort Analysis. <i>Vaccines</i> , 2021, 9, 1146.	4.4	9
11	Immune Responses to Varicella-Zoster Virus Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 223-246.	1.1	3
12	96. Relative Vaccine Effectiveness Against Influenza-Related and Any Respiratory-Related Hospital Encounter During the 2019/20 High Influenza Activity Period: A Comprehensive Real-World Analysis to Compare Quadrivalent Cell-based and Egg-based Influenza Vaccines. <i>Open Forum Infectious Diseases</i> , 2021, 8, S61-S61.	0.9	0
13	LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults. <i>Open Forum Infectious Diseases</i> , 2021, 8, S810-S810.	0.9	27
14	25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season. <i>Open Forum Infectious Diseases</i> , 2021, 8, S136-S136.	0.9	2
15	26. Is There a Correlation Between Reactogenicity and Immune Responses of the Adjuvanted Recombinant Zoster Vaccine (RZV)? A Post-hoc Analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, S136-S136.	0.9	0
16	1341. Relative Vaccine Effectiveness Against Influenza-related Hospitalizations and Respiratory Events During the 2019/20 Influenza seAson in U.S. Children and Adults. A Real-World Evidence Comparison Between Quadrivalent Cell-based and Egg-based Influenza Vaccines. <i>Open Forum Infectious Diseases</i> , 2021, 8, S758-S758.	0.9	0
17	Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain?. <i>Vaccine</i> , 2020, 38, 150-157.	3.8	8
18	Safety and Varicella Outcomes in In Uteroâ€“Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 449-453.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2628-2633.	3.3	13
20	Herpes Zoster and Its Prevention by Vaccination. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2020, 43, 131-145.	2.6	9
21	5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies. <i>Open Forum Infectious Diseases</i> , 2020, 7, S2-S3.	0.9	0
22	Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1231-1238.	3.6	36
23	Evaluation of two frailty indices, with practical application in a vaccine clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2960-2968.	3.3	9
24	Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. <i>PLoS ONE</i> , 2019, 14, e0217749.	2.5	37
25	Immune responses to zoster vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 772-777.	3.3	28
26	Costs of herpes zoster complications in older adults: A cohort study of US claims database. <i>Vaccine</i> , 2019, 37, 1235-1244.	3.8	19
27	Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2865-2872.	3.3	22
28	The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. <i>Journal of Virology</i> , 2019, 93, .	3.4	18
29	Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. <i>Current Opinion in Immunology</i> , 2019, 59, 42-48.	5.5	68
30	Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2466-2474.	3.3	5
31	Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. <i>Vaccine</i> , 2019, 37, 2482-2493.	3.8	34
32	2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1. <i>Open Forum Infectious Diseases</i> , 2019, 6, S981-S982.	0.9	1
33	2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine. <i>Open Forum Infectious Diseases</i> , 2019, 6, S980-S981.	0.9	0
34	A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®. <i>Vaccine</i> , 2019, 37, 5788-5795.	3.8	3
35	The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1217-1224.	3.6	20
36	Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. <i>Journal of Infectious Diseases</i> , 2018, 217, 1750-1760.	4.0	132

#	ARTICLE	IF	CITATIONS
37	Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 603-606.	1.1	9
38	Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. <i>Vaccine</i> , 2018, 36, 1537-1541.	3.8	31
39	Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children. <i>Aids</i> , 2018, 32, 851-860.	2.2	14
40	Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 217, 1055-1059.	4.0	8
41	Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. <i>Vaccine</i> , 2018, 36, 179-185.	3.8	22
42	Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 527-533.	2.1	7
43	2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults. <i>Open Forum Infectious Diseases</i> , 2018, 5, S746-S747.	0.9	1
44	Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. <i>Vaccine</i> , 2018, 36, 6810-6818.	3.8	14
45	Herpes Zoster Vaccines. <i>Journal of Infectious Diseases</i> , 2018, 218, S127-S133.	4.0	29
46	Comparative Immune Responses to Licensed Herpes Zoster Vaccines. <i>Journal of Infectious Diseases</i> , 2018, 218, S81-S87.	4.0	31
47	B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine. <i>Frontiers in Immunology</i> , 2018, 8, 2002.	4.8	11
48	Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1-Infected Infants. <i>Journal of Infectious Diseases</i> , 2018, 218, 1085-1089.	4.0	13
49	Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. <i>Vaccine</i> , 2017, 35, 1712-1720.	3.8	25
50	Metabolic Phenotypes of Response to Vaccination in Humans. <i>Cell</i> , 2017, 169, 862-877.e17.	28.9	234
51	Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. <i>Journal of Immunology</i> , 2017, 199, 604-612.	0.8	33
52	An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. <i>Journal of Infectious Diseases</i> , 2017, 216, 1362-1370.	4.0	88
53	Studies with herpes zoster vaccines in immune compromised patients. <i>Expert Review of Vaccines</i> , 2017, 16, 1217-1230.	4.4	21
54	Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. <i>Aids</i> , 2017, 31, 49-59.	2.2	22

#	ARTICLE	IF	CITATIONS
55	Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1â€“Infected African Infants and Rotavirus Vaccine Responses. <i>Journal of Infectious Diseases</i> , 2017, 215, 928-932.	4.0	13
56	Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 915-922.	9.1	38
57	Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. <i>New England Journal of Medicine</i> , 2016, 375, 1019-1032.	27.0	752
58	Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. <i>Journal of Infectious Diseases</i> , 2016, 213, 14-22.	4.0	69
59	Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. <i>New England Journal of Medicine</i> , 2015, 372, 2087-2096.	27.0	1,040
60	Varicella-Zoster Virus Infections in Patients Treated With Fingolimod. <i>JAMA Neurology</i> , 2015, 72, 31.	9.0	142
61	Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1170-1177.	1.1	1
62	Long-term Persistence of Zoster Vaccine Efficacy. <i>Clinical Infectious Diseases</i> , 2015, 60, 900-909.	5.8	240
63	Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV. <i>PLoS Pathogens</i> , 2014, 10, e1004008.	4.7	36
64	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet</i> , The, 2014, 384, 2213-2227.	13.7	153
65	Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years. <i>Clinical Infectious Diseases</i> , 2012, 54, 922-928.	5.8	388
66	Effect of a Zoster Vaccine on Herpes Zosterâ€“Related Interference with Functional Status and Healthâ€“Related Qualityâ€“ofâ€“Life Measures in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1634-1641.	2.6	89
67	Influence of Age and Nature of Primary Infection on Varicellaâ€“Zoster Virusâ€“Specific Cellâ€“Mediated Immune Responses. <i>Journal of Infectious Diseases</i> , 2010, 201, 1024-1030.	4.0	110
68	VZV T Cell-Mediated Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2010, 342, 341-357.	1.1	164
69	Herpes Zoster with Skin Lesions and Meningitis Caused by 2 Different Genotypes of the Oka Varicellaâ€“Zoster Virus Vaccine. <i>Journal of Infectious Diseases</i> , 2008, 198, 1444-1447.	4.0	65
70	Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIVâ€“Infected Patients. <i>Clinical Infectious Diseases</i> , 2004, 39, S248-S257.	5.8	112
71	Structural Validation of the Hamilton Depression Rating Scale. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2004, 26, 241-254.	1.2	24
72	Development of Resistance to Acyclovir during Chronic Infection with the Oka Vaccine Strain of Varicellaâ€“Zoster Virus, in an Immunosuppressed Child. <i>Journal of Infectious Diseases</i> , 2003, 188, 954-959.	4.0	134

#	ARTICLE	IF	CITATIONS
73	Varicella-Zoster Virus DNA in Cells Isolated from Human Trigeminal Ganglia. <i>Journal of Virology</i> , 2003, 77, 6979-6987.	3.4	82
74	Frequency of Acyclovir-Resistant Herpes Simplex Virus in Clinical Specimens and Laboratory Isolates. <i>Journal of Clinical Microbiology</i> , 2001, 39, 913-917.	3.9	41
75	Sabin attenuated LSc/2ab strain of poliovirus spreads to the spinal cord from a peripheral nerve in bonnet monkeys ( <i>Macaca radiata</i> ). <i>Journal of General Virology</i> , 2001, 82, 1329-1338.	2.9	4
76	Reduced cellular immunity to varicella zoster virus during treatment for acute lymphoblastic leukemia of childhood: In Vitro studies of possible mechanisms. <i>Journal of Clinical Immunology</i> , 1986, 6, 472-480.	3.8	12